We determined the serum GP73 concentration in MASLD patients and healthy controls and showed that the serum GP73 concentration is higher in patients with significant fibrosis with respect to controls and non-significant fibrosis. Here, GOLM1 is linked to metabolic dysfunction-associated steatotic liver disease.